Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
ID06076304

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

Led by Daniel Merenstein · Updated on 2026-03-03

3720

Participants Needed

7

Research Sites

8 weeks

Total Duration

On this page

Sponsors

D

Daniel Merenstein

Lead Sponsor

P

Patient-Centered Outcomes Research Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

Acute sinus infections, also called acute rhinosinusitis (ARS), affect about 15% of adults annually and are a common reason for antibiotic prescriptions despite most cases being caused by viruses. This research aims to understand which patients with ARS truly benefit from antibiotics and other treatments, improving care by identifying subgroups that respond best to specific therapies. The study is a large, pragmatic, randomized controlled trial enrolling adults aged 18 to 75 with symptoms consistent with ARS. Participants enter two phases: Phase 1 is a waiting period of up to 9 days with options for supportive care, during which symptom progress is monitored. Those who do not improve or who meet certain criteria move to Phase 2, where they are randomly assigned to one of four groups receiving either amoxicillin/clavulanate, placebo antibiotic, amoxicillin/clavulanate plus budesonide nasal spray, or placebo antibiotic plus budesonide. Treatments are given over 7 to 14 days, with dosing schedules including oral antibiotics twice daily and budesonide nasal spray once daily. Throughout both phases, participants complete daily diaries and periodic follow-ups to track symptom changes, supportive care use, and side effects. Researchers measure symptom improvement from day 1 to day 3 in Phase 2 as the primary outcome, along with additional assessments of quality of life, work productivity, adherence, and adverse events. The total study period includes up to 9 days of observation and 14 days of randomized treatment with ongoing monitoring to better target effective management for ARS.

CONDITIONS

Brief Title

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • Symptoms compatible with acute rhinosinusitis lasting 1 to 21 days without improvement
  • Or worsening symptoms (new fever, headache, or increased nasal discharge) after initial improvement from a viral upper respiratory infection
Not Eligible

You will not qualify if you...

  • Allergy or intolerance to penicillin
  • Received systemic antibiotics in the past 4 weeks
  • Prior sinus surgery (except cosmetic procedures)
  • Sinusitis complications such as swelling, cellulitis, or signs affecting eyes or brain
  • Need for intravenous antibiotics or hospital admission
  • Pregnancy or breastfeeding
  • Comorbidities or medications impairing immune response as determined by a clinician
  • Hospitalization in the past 5 days
  • Unable or unwilling to provide informed consent or comply with study requirements
  • Fever over 39°C (102°F) at screening
  • Regular use of intranasal corticosteroids in the past two weeks and unwilling to stop
  • Previous participation in this study phase or feasibility phase

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Pre-randomization Waiting Period

Duration - Up to 9 days

Participants complete up to 9 days of supportive care and daily symptom diaries while their symptoms are monitored before potential randomization.

Daily symptom diary entries and periodic follow-ups on Days 1, 3, 5, 7, 10, and 14

Treatment

Duration - 14 days

Participants who do not improve during the waiting period or meet criteria are randomly assigned to receive one of four interventions involving antibiotics and/or intranasal corticosteroids for 14 days.

Daily symptom diary entries and assessments on Days 1, 7, and 14

Trial Site Locations

Total: 7 locations

1

University of California, Los Angeles

Los Angeles, California, United States, 90095

Actively Recruiting

2

Georgetown University Medical Center

Washington D.C., District of Columbia, United States, 20007

Actively Recruiting

3

MedStar Health Research Institute

Hyattsville, Maryland, United States, 20782

Not Yet Recruiting

4

Penn State College of Medicine

Hershey, Pennsylvania, United States, 17033

Actively Recruiting

5

Virginia Commonwealth University

Richmond, Virginia, United States, 23219

Actively Recruiting

6

University of Washington

Seattle, Washington, United States, 98195

Actively Recruiting

7

University of Wisconsin-Madison

Madison, Wisconsin, United States, 53705

Actively Recruiting

Loading map...

Research Team

L

Lead Project Coordinator

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

TREATMENT

Number of Arms

4

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here